Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators.

N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914510. [Epub ahead of print]

PMID:
31825192
2.

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.

Breast Cancer. 2019 Dec 6. doi: 10.1007/s12282-019-01029-3. [Epub ahead of print]

PMID:
31811519
3.

Risk factors for early postoperative psychological problems in breast cancer patients after axillary lymph node dissection.

Akezaki Y, Nakata E, Kikuuchi M, Tominaga R, Kurokawa H, Hamada M, Aogi K, Ohsumi S, Sugihara S.

Breast Cancer. 2019 Nov 2. doi: 10.1007/s12282-019-01020-y. [Epub ahead of print]

PMID:
31679113
4.

Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.

Matsui A, Murata Y, Masuda N, Mori K, Takahashi M, Yamashiro K, Aogi K, Maeda S, Itou M, Ozaki S, Kuraoka K, Satou Y, Ichihara S, Tokunaga E, Taguchi K, Watanabe T, Suzuki H, Nagayama A, Nishimura R.

Oncotarget. 2019 Oct 1;10(55):5680-5689. doi: 10.18632/oncotarget.27163. eCollection 2019 Oct 1.

5.

A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.

Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Miyashita M, Iijima K, Hayashi N, Yamamoto Y, Imoto S, Jinno H.

Breast Cancer Res Treat. 2019 Dec;178(3):647-656. doi: 10.1007/s10549-019-05413-7. Epub 2019 Aug 26.

6.

Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.

Hida AI, Watanabe T, Sagara Y, Kashiwaba M, Sagara Y, Aogi K, Ohi Y, Tanimoto A.

Breast Cancer Res Treat. 2019 Nov;178(2):283-294. doi: 10.1007/s10549-019-05390-x. Epub 2019 Aug 12.

PMID:
31402409
7.

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.

Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.

Transl Oncol. 2019 Oct;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. Epub 2019 Aug 2.

8.

Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.

Hojo T, Masuda N, Iwamoto T, Niikura N, Anan K, Aogi K, Ohnishi T, Yamauchi C, Yoshida M, Kinoshita T, Masuoka H, Sagara Y, Sakatani T, Kojima Y, Tsuda H, Kumamaru H, Miyata H, Nakamura S.

Breast Cancer. 2020 Jan;27(1):85-91. doi: 10.1007/s12282-019-00997-w. Epub 2019 Jul 20.

PMID:
31327134
9.

Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry.

Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Tsuda H, Nakamura S, Tokuda Y.

Ann Surg Oncol. 2019 Aug;26(8):2475-2485. doi: 10.1245/s10434-019-07453-1. Epub 2019 May 17.

PMID:
31102090
10.

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M.

ESMO Open. 2019 Feb 27;4(1):e000476. doi: 10.1136/esmoopen-2018-000476. eCollection 2019.

11.

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.

Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.

PMID:
30703739
12.

The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer.

Takabatake D, Kajiwara Y, Ohtani S, Itano Y, Yamamoto M, Kubo S, Ikeda M, Takahashi M, Hara F, Aogi K, Ohsumi S, Ogasawara Y, Nishiyama Y, Hikino H, Matsuoka K, Takahashi Y, Shien T, Taira N, Doihara H.

Breast Cancer. 2018 Nov;25(6):717-722. doi: 10.1007/s12282-018-0877-1. Epub 2018 Jun 11.

PMID:
29948957
13.

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.

Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.

Breast. 2018 Aug;40:67-75. doi: 10.1016/j.breast.2018.04.010. Epub 2018 Apr 23.

PMID:
29698927
14.

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M.

ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.

15.

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.

Curr Med Res Opin. 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426. Epub 2017 Nov 21.

PMID:
29095648
16.

Job resignation after cancer diagnosis among working survivors in Japan: timing, reasons and change of information needs over time.

Takahashi M, Tsuchiya M, Horio Y, Funazaki H, Aogi K, Miyauchi K, Arai Y.

Jpn J Clin Oncol. 2018 Jan 1;48(1):43-51. doi: 10.1093/jjco/hyx143.

PMID:
29036512
17.

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.

Ohgami M, Bando H, Ishiguro H, Tsuda M, Toriguchi N, Aogi K, Toi M, Masuda N, Mitsuhashi S, Kurosawa A, Homma M.

Ann Oncol. 2017 Nov 1;28(11):2888-2889. doi: 10.1093/annonc/mdx328. No abstract available.

18.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M.

N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.

19.

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M.

Breast Cancer Res Treat. 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23.

PMID:
28337663
20.

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y.

Cancer Sci. 2017 May;108(5):987-994. doi: 10.1111/cas.13221. Epub 2017 May 5.

21.
22.

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

Mukai H, Saeki T, Aogi K, Naito Y, Matsubara N, Shigekawa T, Ueda S, Takashima S, Hara F, Yamashita T, Ohwada S, Sasaki Y.

Cancer Sci. 2016 Oct;107(10):1465-1470. doi: 10.1111/cas.13017. Epub 2016 Sep 15.

23.

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.

Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Kinoshita T, Nakamura S, Tokuda Y.

Breast Cancer Res Treat. 2016 Nov;160(1):163-172. Epub 2016 Sep 19.

24.

Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.

Masuda N, Iwata H, Aogi K, Xu Y, Ibrahim A, Gao L, Dalal R, Yoshikawa R, Sasaki Y.

Jpn J Clin Oncol. 2016 Dec;46(12):1088-1094. Epub 2016 Sep 8.

PMID:
27608646
25.

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.

Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y.

Breast Cancer Res Treat. 2016 Jul;158(1):1-9. doi: 10.1007/s10549-016-3848-2. Epub 2016 Jun 3.

26.

Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.

Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T.

Support Care Cancer. 2016 Sep;24(9):4025-33. doi: 10.1007/s00520-016-3203-5. Epub 2016 Apr 29.

27.

Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry.

Iwamoto T, Kumamaru H, Miyata H, Tomotaki A, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Matsuoka J, Doihara H, Kinoshita T, Nakamura S, Tokuda Y.

Breast Cancer Res Treat. 2016 Apr;156(3):485-494. doi: 10.1007/s10549-016-3770-7. Epub 2016 Apr 5.

28.

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.

Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M.

BMC Cancer. 2016 Mar 16;16:230. doi: 10.1186/s12885-016-2270-9.

29.

Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.

Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y.

Cancer Med. 2016 Jun;5(6):1328-40. doi: 10.1002/cam4.678. Epub 2016 Feb 29.

30.

Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.

Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y.

Ann Oncol. 2016 Mar;27(3):480-7. doi: 10.1093/annonc/mdv611. Epub 2015 Dec 23.

31.

Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006.

Iwamoto T, Fukui N, Kinoshita T, Anan K, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y.

Breast Cancer. 2016 Jan;23(1):62-72. doi: 10.1007/s12282-015-0646-3. Epub 2015 Oct 13. No abstract available.

32.

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005.

Anan K, Fukui N, Kinoshita T, Iwamoto T, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y.

Breast Cancer. 2016 Jan;23(1):50-61. doi: 10.1007/s12282-015-0645-4. Epub 2015 Oct 13. No abstract available.

33.

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004.

Kinoshita T, Fukui N, Anan K, Iwamoto T, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y.

Breast Cancer. 2016 Jan;23(1):39-49. doi: 10.1007/s12282-015-0644-5. Epub 2015 Oct 7. No abstract available.

34.

Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.

Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Udagawa Y, Okawa Y, Onozawa Y, Sasaki H, Shima Y, Shimoyama N, Takeda M, Nishidate T, Yamamoto A, Ikeda T, Hirata K.

Int J Clin Oncol. 2016 Feb;21(1):1-12. doi: 10.1007/s10147-015-0852-1. Epub 2015 Jun 17.

35.

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.

Inoue K, Kuroi K, Shimizu S, Rai Y, Aogi K, Masuda N, Nakayama T, Iwata H, Nishimura Y, Armour A, Sasaki Y.

Int J Clin Oncol. 2015 Dec;20(6):1102-9. doi: 10.1007/s10147-015-0832-5. Epub 2015 May 13.

36.

[The survey for anti-emetic guideline by using questioner].

Saeki T, Tamura K, Aiba K, Aogi K, Iino K, Imamura C, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Matsuura K, Wada M, Akechi T, Kakudo Y, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Saito M, Ashikaga Y, Tanigawara Y, Hirata K, Ishioka C, Nishiyama M.

Gan To Kagaku Ryoho. 2015 Mar;42(3):305-11. Japanese.

PMID:
25812498
37.

Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer.

Takashima S, Kiyoto S, Takahashi M, Hara F, Aogi K, Ohsumi S, Mukai R, Fujita Y.

Oncol Lett. 2015 Apr;9(4):1822-1826. Epub 2015 Feb 10.

38.

Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.

Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N, Okada M.

Breast Cancer Res Treat. 2015 Feb;150(1):209-17. doi: 10.1007/s10549-015-3303-9. Epub 2015 Feb 20.

39.

Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.

Hida AI, Bando K, Sugita A, Maeda T, Ueda N, Matsukage S, Nakanishi M, Kito K, Miyazaki T, Ohtsuki Y, Oshiro Y, Inoue H, Kawaguchi H, Yamashita N, Aogi K, Moriya T.

J Clin Pathol. 2015 May;68(5):356-61. doi: 10.1136/jclinpath-2014-202695. Epub 2015 Feb 11.

PMID:
25673730
40.

Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.

Yamamoto H, Ando M, Aogi K, Iwata H, Tamura K, Yonemori K, Shimizu C, Hara F, Takabatake D, Hattori M, Asakawa T, Fujiwara Y.

Jpn J Clin Oncol. 2015 Jan;45(1):12-8. doi: 10.1093/jjco/hyu160. Epub 2014 Oct 20.

PMID:
25332421
41.

Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.

Aihara T, Yokota I, Hozumi Y, Aogi K, Iwata H, Tamura M, Fukuuchi A, Makino H, Kim R, Andoh M, Tsugawa K, Ohno S, Yamaguchi T, Ohashi Y, Watanabe T, Takatsuka Y, Mukai H.

Breast Cancer Res Treat. 2014 Nov;148(2):337-43. doi: 10.1007/s10549-014-3155-8. Epub 2014 Oct 16.

PMID:
25318924
42.

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404.

Shien T, Iwata H, Fukutomi T, Inoue K, Aogi K, Kinoshita T, Ando J, Takashima S, Nakamura K, Shibata T, Fukuda H.

Cancer Chemother Pharmacol. 2014 Sep;74(3):603-9. doi: 10.1007/s00280-014-2545-2. Epub 2014 Jul 24.

43.

Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer.

Nishimura R, Kagawa A, Tamogami S, Kojima K, Satou M, Yamashita N, Teramoto N, Aogi K.

Breast Cancer. 2016 Mar;23(2):211-5. doi: 10.1007/s12282-014-0552-0. Epub 2014 Jul 18.

PMID:
25033760
44.

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.

Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y.

Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12.

PMID:
24728578
45.

[II.Late recurrence and resistance 2. Overcoming a trial for acquired resistance against hormone therapy for breast cancer].

Aogi K.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2510-3. Japanese. No abstract available.

PMID:
24422238
46.

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).

Shien T, Iwata H, Aogi K, Fukutomi T, Inoue K, Kinoshita T, Takahashi M, Matsui A, Shibata T, Fukuda H.

Int J Clin Oncol. 2014 Dec;19(6):982-8. doi: 10.1007/s10147-013-0657-z. Epub 2014 Jan 7.

PMID:
24395447
47.

Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCOG0306.

Mukai H, Watanabe T, Mitsumori M, Tsuda H, Nakamura S, Masuda N, Yamamoto N, Shibata T, Sato A, Iwata H, Aogi K.

Oncology. 2013;85(6):336-41. doi: 10.1159/000355196. Epub 2013 Nov 12.

PMID:
24247597
48.

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.

Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M.

Breast Cancer Res Treat. 2013 Nov;142(1):69-80.

49.

Association of positive EBAG9 immunoreactivity with unfavorable prognosis in breast cancer patients treated with tamoxifen.

Ijichi N, Shigekawa T, Ikeda K, Miyazaki T, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Clin Breast Cancer. 2013 Dec;13(6):465-70. doi: 10.1016/j.clbc.2013.08.015. Epub 2013 Oct 8.

PMID:
24119785
50.

[Clinical experience with gemcitabine treatment for metastatic breast cancer].

Watanabe M, Hara F, Kiyoto S, Takahashi M, Takabatake D, Takashima S, Aogi K, Ohsumi S.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1355-9. Japanese.

PMID:
24105058

Supplemental Content

Support Center